BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12883632)

  • 1. [Biological function of fusion protein ATF-PAI2CD].
    Wang X; Li P; Zhang YQ; Hou M; Sun XH; Tan L; Zhu YS
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):624-8. PubMed ID: 12883632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
    Wang X; Hou M; Tan L; Sun X; Zhang Y; Li P; Zhu Y
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):129-36. PubMed ID: 15490235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
    Zhu F; Xing G; He F
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli.
    Hua ZC; Chen XC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 May; 222(2):576-83. PubMed ID: 8670247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.
    Zhao G; Yuan C; Bian C; Hou X; Shi X; Ye X; Huang Z; Huang M
    Protein Expr Purif; 2006 Sep; 49(1):71-7. PubMed ID: 16806969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical Characterization of PAI-2 and Its Mutants.
    Tian Y; Shen JQ; Li P; Zhu YS
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2000; 32(2):126-132. PubMed ID: 12098788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
    Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
    Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The functional expression of humanized ScFv-urokinase fusion protein in Escherichia coli].
    Liu ZG; Lin JB; Yuan XD; Kang TJ; Yu WY
    Sheng Wu Gong Cheng Xue Bao; 2002 Jul; 18(4):509-11. PubMed ID: 12385254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
    Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
    Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
    Al-Ejeh F; Croucher D; Ranson M
    Exp Cell Res; 2004 Jul; 297(1):259-71. PubMed ID: 15194441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.